SCHEMBL334235

SCHEMBL334235

CC(C)Oc1ccc(Oc2ccc3c(c2)c(C(=O)O)c(CC(=O)O)n3-c2ccc(C(C)C)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 2/20 0.42
MDM2 Q00987 2/20 0.42
MCL1 Q07820 2/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CASR P41180 1/20 0.40
USP14 P54578 1/20 0.40
KDM4E B2RXH2 2/20 0.40
PTGES O14684 3/20 0.38
GAA P10253 1/20 0.38
PTGDR Q13258 1/20 0.36
PLA2G4A P47712 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 2/20 0.35
ACACB O00763 1/20 0.35
ACACA Q13085 1/20 0.35
ALDH1A1 P00352 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
THRB P10828 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL503872 0.92 USP14 (0.48) MEN1KMT2AUSP14KDM4EPTGES
SCHEMBL333231 0.91 MEN1 (0.48) MEN1KMT2AUSP14KDM4EPTGES
SCHEMBL333959 0.91 USP14 (0.49) MEN1KMT2AUSP14KDM4EPTGES
SCHEMBL503756 0.89 USP14 (0.45) BCL2MDM2MCL1MEN1KMT2A
SCHEMBL334350 0.89 PTGES (0.52) MEN1KMT2AKDM4EPTGES
SCHEMBL334287 0.88 FFAR1 (0.43) MEN1KMT2AUSP14KDM4EGAA
SCHEMBL333497 0.88 USP14 (0.44) BCL2MDM2MCL1MEN1KMT2A
SCHEMBL334349 0.88 PPARG (0.44) MEN1KMT2APTGES
SCHEMBL334171 0.88 PPARG (0.47) MEN1KMT2AUSP14
SCHEMBL504356 0.88 PPARG (0.42) BCL2MDM2MCL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097623-B2 1-Aryl-or heteroaryl-3-aryl-or heteroarylindole-2-carboxylic acids or esters: e.g., 5-(4-tert-Butylphenyl)-1,3-bis(4-isopropoxyphenyl)-indole-2-carboxylic acid; inhibition of the activity of microsomal prostaglandin E synthase-1, leukotriene C4 and/or 5-lipoxygenase-activating protein; analgesics BIOLIPOX AB (SE) 2012-01-17 US disclosed
EP-1841735-B1 INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION BIOLIPOX AB (SE) 2011-03-09 EP disclosed
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076004-A1 Indoles Useful in the Treatment of Inflammation IDO1, IDO2, AREG BCL2 325/4885MDM2 917/4885MCL1 880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.